scispace - formally typeset
H

Hokyung K. Chung

Researcher at Stanford University

Publications -  9
Citations -  589

Hokyung K. Chung is an academic researcher from Stanford University. The author has contributed to research in topics: Protein engineering & Degron. The author has an hindex of 6, co-authored 9 publications receiving 476 citations. Previous affiliations of Hokyung K. Chung include Seoul National University.

Papers
More filters
Journal ArticleDOI

Optical control of protein activity by fluorescent protein domains

TL;DR: Light-dependent dissociation and association in a mutant of the photochromic FP Dronpa is described and used to control protein activities with light, extending the applications of FPs from exclusively sensing functions to also encompass optogenetic control.
Journal ArticleDOI

Tunable and reversible drug control of protein production via a self-excising degron.

TL;DR: Small Molecule-Assisted Shutoff (SMASh), a technique in which proteins are fused to a degron that removes itself in the absence of drug, leaving untagged protein, is described.
Journal ArticleDOI

A Single-Chain Photoswitchable CRISPR-Cas9 Architecture for Light-Inducible Gene Editing and Transcription

TL;DR: This design successfully controlled different species and functional variants of Cas9, mediated transcriptional activation more robustly than previous optogenetic methods, and enabled light-induced transcription of one gene and editing of another in the same cells.
Journal ArticleDOI

Replication-Competent Influenza Virus and Respiratory Syncytial Virus Luciferase Reporter Strains Engineered for Co-Infections Identify Antiviral Compounds in Combination Screens

TL;DR: An RSV strain carrying firefly luciferase fused to an innovative universal small-molecule assisted shut-off domain, which boosted assay signal window, and a hyperactive fusion protein that synchronized IAV and RSV reporter expression kinetics and suppressed the identification of RSV entry inhibitors sensitive to a recently reported RSV pan-resistance mechanism are developed.
Journal ArticleDOI

A compact synthetic pathway rewires cancer signaling to therapeutic effector release.

TL;DR: Rewiring of Aberrant Signaling to Effector Release (RASER), in which a compact synthetic signaling pathway detects an oncogenic signal with high specificity and then rewires it to a variety of customizable responses.